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Abstract
Background: Loss of PTEN is involved in tumor progression of several tumor entities including renal cell carcinoma
(RCC). During the translation process PTEN generates a number of splice variants, including PTEN-Δ. We analyzed
the impact of PTEN-Δ in RCC progression.
Methods: In specimens of RCC patients the expression of PTEN-Δ and PTEN was quantified. The PTEN expressing
RCC cell line A498 and the PTEN deficient 786-O cell line were stably transfected with the PTEN-Δ or PTEN
transcript. In Caki-1 cells that highly express PTEN-Δ, this isoform was knocked down by siRNA. Cell migration,
adhesion, apoptosis and signaling pathways activities were consequently analyzed in vitro.
Results: Patients with a higher PTEN-Δ expression had a longer lymph node metastasis free and overall survival. In
RCC specimens, the PTEN-Δ expression correlated with the PTEN expression. PTEN-Δ as well as PTEN induced a
reduced migration when using extracellular matrix (ECM) compounds as chemotaxins. This effect was confirmed by
knockdown of PTEN-Δ, inducing an enhanced migration. Likewise a decreased adhesion on these ECM components
could be shown in PTEN-Δ and PTEN transfected cells. The apoptosis rate was slightly increased by PTEN-Δ. In a
phospho-kinase array and Western blot analyses a consequently reduced activity of AKT, p38 and JNK could be
shown.
Conclusions: We could show that the PTEN splice variant PTEN-Δ acts similar to PTEN in a tumor suppressive
manner, suggesting synergistic effects of the two isoforms. The impact of PTEN-Δ in context of tumor progression
should thus be taken into account when generating new therapeutic options targeting PTEN signaling in RCC.
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Background
PTEN (Phosphatase and Tensin homolog on chromo-
some 10) encodes a tumor suppressor protein with dual
specific protein and phospholipid phosphatase activity
[1]. It is expressed ubiquitously and mediates cellular
processes like adhesion, migration, cell survival and
apoptosis [2]. The gene, located on chromosome
10q23.3, consists of 9 exons. The PTEN protein consists
of 403 amino acids that are divided in five functional do-
mains. From N-terminal to C-terminal PTEN includes a
PBD-binding domain, a phosphatase domain, a C2 do-
main, a C-tail domain and a PDZ-binding domain (Fig. 1)
[3]. The phosphatase domain comprises the catalytic
center where the phosphatase dephosphorylates poly-
peptides or inositol rings [4]. The other domains take
part in the subcellular localization and regulate the pro-
tein’s activity and degradation. Especially the C-terminal
domains carry a lot of modification and protein-protein
interaction sites [3].
In many tumor entities PTEN is inactive due to muta-
tions, deletions or epigenetic changes [5–7]. The tumor
suppressor is involved in several signaling pathways
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which can trigger tumor progression processes. By de-
phosphorylation of PtdIns(3,4,5)P3 (phosphatidylinositol
3,4,5-triphosphate) in the 3-position of the inositol ring
[8], PTEN inhibits activation of the AKT signaling cas-
cade and therefore reduces cell migration and adhesion
and induces apoptosis [9–12]. Furthermore PTEN is able
to dephosphorylate FAK (focal adhesion kinase) and
SHC (SRC homology 2 domain containing) by its pro-
tein phosphatase activity. By doing so, PTEN regulates
the interaction with the extracellular matrix (ECM), in-
hibits the MAPK (mitogen-activated protein kinase)
pathway and hence modifies again cellular processes like
proliferation, migration and adhesion [13, 14].
During mRNA processing PTEN generates a number
of splice variants. Until now, ten different splice iso-
forms have been described [15, 16], eight of which in-
clude intron sequences in the open reading frame.
PTEN-B, SV-5a, SV-5b and SV-5c contain parts of in-
tron 5 and SV-3a, SV-3b and SV-3c contain parts of in-
tron 3. The splice variant PTEN-Δ results from
integration of intron 8 into the mRNA. In this splice
variant the 61 amino acids of exon 9 are replaced by a
valine and serine from intron 8, followed by a STOP
codon (Fig. 1) [16]. Two other splice variants, SV-DelE5
and SV-DelE6, are generated by deletion of exon se-
quences. All splice variants lead to shorter protein se-
quences [15]. Agrawal and colleagues could show that
SV-5c, SV-3b, SV-3c and SV-DelE6 are lower expressed
in breast cancer specimens than in the corresponding
healthy tissue. In contrast splice variant SV-5b showed a
higher expression in the tumors [15]. However, the pre-
cise potential of the PTEN splice variants in tumor pro-
gression is still questionable and has to be determined in
further studies.
In the presented study we analyzed the impact of the
splice variant PTEN-Δ on tumor progression of renal
cell carcinoma (RCC). We analyzed the PTEN-Δ
expression values in RCC specimens and compared
them with the survival rate and the status of metastasis.
We demonstrate that PTEN-Δ is translated in RCC cell
lines and analyzed the effect of PTEN-Δ overexpression
or silencing on specific steps of tumor progression and
metastasis in vitro.
Methods
Specimens
Primary RCC tissue samples were obtained under sterile
conditions from 71 patients (Table 1) who underwent
nephrectomy at the Department of Urology, University
Medical Center Mainz [17]. The study was performed in
agreement with the Declaration of Helsinki and ap-
proved by local ethics committee (No. 837.005.09, Land-
esärztekammer Rheinland-Pfalz, Mainz, Germany). Each
patient provided informed consent. Samples of tumor
tissue and renal cortex, obtained from the opposite kid-
ney pole at a minimum distance of 3 cm from the tumor,
were shock frozen in liquid nitrogen and stored at − 80 °
C. The RCC diagnosis and tumor grade was verified on
hematoxylin and eosin sections.
RNA extraction
RNA was extracted from the frozen tissue samples by
using the PeqGold Total RNA Kit (Peqlab). The tissue
was first split into pieces of 40–50 mg and then
Fig. 1 Schematic illustration of PTEN-Δ and PTEN. The nine
exons of the PTEN gene are represented as boxes. PTEN-Δ lacks
the coding potential of exon 9 due to inclusion of intron 8. The
PTEN protein is composed of five domains: PBD-, Phosphatase,
C2-, C-tail- and PDZ-binding Domain, PTEN-Δ consequently lacks
parts of the C2 domain, the C-tail and the PDZ-binding domain
Table 1 Patient Data
frequency
gender male 49
female 22
histology clear cell 62
papillary 9
pT-stage 1 23
2 14
3 34
4 0
grading 1 3
2 39
3 25
4 3
metastasis during follow-up Yes 33
No 34
Unknown 4
age (years) Median 61.33
follow-up (months) Median 60.07
Min 0.93
Max 172.40
Overview of the composition of the analyzed patient cohort. The short
minimal follow-up resulted from an early death of one patient
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transferred in Precellys ceramic tubes. Afterwards the
samples were homogenized by adding 400 μl of RNA
lysis buffer T (Peqlab) followed by incubation in a Pre-
cellys homogenizer on a frequence of 5000 rpm for 3 ×
45 seconds. In contrast cultivated cell lines were lysed
by adding 600 μl of RNA lysis buffer T and detached by
using a scraper. Afterwards the samples were processed
according to the kit-provider. To ensure a completely
DNA free RNA extract an additional enzymatic digestion
of DNA with DNase (Peqlab) was performed after the
first washing step for 15 min at room temperature (RT).
The amount of RNA in each sample was photometrically
determined, using the Nanodrop1000 (Thermo
Scientific).
cDNA synthesis
RNA was transformed into cDNA with M-MLV reverse
transcriptase (Invitrogen). Therefore 2–3 μg of isolated
RNA was diluted in 20 μl RNase free water and dena-
tured at 70 °C for 10 min. Next a reaction mix was
added to every sample, each containing 1 μl oligo-dT
primer (0.5 μg/μl), 2 μl RNase inhibitor, 3.5 μl dNTP
mix (each 2.5 mM), 4 μl DTT (0.1 M), 8 μl of First
strand buffer (0.1 M) and finally 1.5 μl M-MLV reverse
transcriptase. Subsequently, the samples were incubated
at 37 °C for 90 min and finally the reverse transcriptase
was inactivated by raising the temperature on 95 °C for
further 10 min.
Real-time PCR
Quantification of gene expression was performed with
the LightCycler 480 II (Roche). Specific primers were
used to secure a selective amplification. These include
the PTEN-specific primers 5‘-GTTTACCGGCAGCA
TCAAAT-3′ (forward) and 5‘-CCCCCACTTTAGTG
CACAGT-3′ (reverse), as well as the PTEN-Δ specific
primers 5‘-TCCACAAACAGAACAAGATGC-3′ (for-
ward) and 5‘-ACACACATCACATACATACAAG-3′ (re-
verse). The primers were added (10 μM each) to a total
mixture of 10 μl, containing 5 μl Kapa SYBR Fast re-
agent (Kapa Biosystems), 3 μl distilled water and 1 μl of
the cDNA sample. Each reaction was performed in du-
plicate and determined by the following program: initial
denaturation (3 min; 95 °C), followed by 45 repetitive cy-
cles, including denaturation (5 s; 95 °C), annealing
(5 sec; 62–66 °C) and elongation (1 s; 72 °C). A final cal-
culation of a melting curve concluded this analytic pro-
cedure. For analysis the geometrical average was
calculated referring to the expression level of the house
keeping genes TBP (TATA-box binding protein), ATP5J
(ATP synthase, mitochondrial F0 complex subunit F6)
and PPIA (peptidylprolyl isomerase A) [18], which were
measured simultaneously.
Cells and cell culture
The human RCC cell lines A498, 786-O, Caki-1 and
Caki-2 were obtained from LGC Promochem and
CCF-RCI and CCF-RCII were kindly provided by the es-
tablisher, Cleveland Clinic Foundation [19]. Caki-1 and
Caki-2 cell culture was maintained in Iscoves medium
(Biochrom), supplemented with 10% fetal calf serum, 1%
GlutaMax (Sigma) and 1× penicillin/streptomycin (Life
Technology). All other cell lines were maintained in
RPMI1640 (Gibco) supplemented with 10% fetal calf
serum, 2.5% HEPES buffer (Sigma) and 1× penicillin/
streptomycin (Life Technology). All cell lines were incu-
bated in a moistened atmosphere at 5% CO2 at 37 °C.
Plasmid construction and stable transfection of RCC cell
lines
ORFs of the PTEN and PTEN-Δ isoforms were PCR
amplified, inserted into a pcDNA3 vector (Invitrogen)
and in frame tagged with a V5 encoding domain. Che-
mocompetent DH5 E. coli cells were transfected with
the expression plasmids. Individual clones were selected
according to their resistance to ampicillin and verified
by complete sequencing of the plasmid insert. For stable
transfection 2 × 105 A498 or 786-O cells were seeded in
a 6-well-plate. Next day 5 μg plasmid DNA was mixed
with 10 μl P3000 (Thermo Scientific) and 125 μl
Opti-Mem (Gibco). At the same time 7.5 μl L3000
(Thermo Scientific) was diluted with 125 μl Opti-Mem.
Both mixtures were combined and after 10 min incuba-
tion the cells were transfected by adding the mixture
dropwise. After 24 h G418 (400 mg/ml) was added to
the cell medium. Cells were cultured and resistant
clones were selected.
In vitro translation
For cell free in vitro translation (IVT) the 1-step human
coupled IVT (Thermo Scientific) kit system was used.
cDNA containing the ORF of the PTEN isoforms was
inserted into the provided pT7CFE1 vector. For IVT
12.5 μl HeLa lysate was mixed with 2.5 μl accessory pro-
teins. After incubation on ice for 10 min, 5 μl reaction
mix, 2 μl of plasmid (0.5 μg/μl) and 3 μl nuclease free
water were added. IVT was performed for 3 h at 30 °C.
Knockdown
PTEN-Δ was selectively knocked down in Caki-1 cells,
using the synthesized ds-siRNA targeting PTEN-Δ:
5’-AAAUUUUAAGGUCAGUUAA-3‘ (sense) and
5’-UUAACUGACCUUAAAAUUU-3′ (antisense) from
Sigma Aldrich. Lipofectamine RNAiMAX (Thermo Sci-
entific) was used as transfection reagent. 2 × 105 cells
were plated in a 6-well-plate and cultured in 2.5 ml
Iscoves medium lacking antibiotics. Each well received
either PTEN-Δ siRNA or scrambled locus siRNA
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(negative control) treatment as reference. In the follow-
ing PTEN-Δ siRNA, or scrambled locus siRNA and Li-
pofectamine RNAiMAX (7.5 μl) were each mixed with
Opti-Mem complete medium (Gibco) to a total concen-
tration of 150 pmol siRNA per well and in a total vol-
ume of 250 μl per well. The diluted transfection reagent
was then mixed with the diluted siRNA solution and
filled dropwise in the correspondent wells. After incuba-
tion at 5% CO2 and 37 °C for 24 h, medium was changed
to Iscoves medium without additives and cells were in-
cubated for another 24 h. Cells from each well were then
detached, counted and prepared for a cell migration
assay. The remaining cells of each sample were centri-
fuged, each suspended in 600 μl RNA lysis buffer T and
frozen at − 80 °C for later RNA extraction.
Cell adhesion assay
For cell adhesion assay amine-binding, maleic anhydride
activated clear 96-well-plates (Pierce #15110, Thermo
Scientific) were used as described previously [20]. Extra-
cellular matrix components used were fibronectin
(10 μg/ml), vitronectin (5 μg/ml), laminin (50 μg/ml),
collagen I (10 μg/ml), collagen IV (10 μg/ml) and as con-
trol BSA (10 μg/ml) (all Thermo Scientific). Concentra-
tions were selected according to the cell migration assay.
Each well was coated with extracellular matrix compo-
nents at a volume of 100 μl overnight on a rocking
shaker at RT and washed twice with 100 μl washing buf-
fer (DPBS with 0.05% Tween 20, ICI Amenic Inc.). Un-
specific binding sites were blocked with 200 μl blocking
solution (DPBS with 0.5% BSA) per well and incubated
for 1 h in a moistened atmosphere at 5% CO2 at 37 °C
in air. Meanwhile cells were washed in DPBS, medium
was then replaced with Trypsin-EDTA and cells were re-
suspended in serum-free culture medium. Blocking solu-
tion was removed from the wells coated with ECM
components and 50 μl of tumor cell suspension were
added (4 × 105 cells/ml) per well. After 1 h incubation in
a moistened atmosphere at 5% CO2 at 37 °C in air,
non-adherent cells were removed with 2 × 200 μl wash-
ing buffer (DPBS with 0.05% Tween 20) per well. Adher-
ent cells were fixed with 100 μl 4% paraformaldehyde
(Histofix 4%, Roth) for 15 min at RT and stained using
100 μl crystal violet solution (5 mg/ml in 2% ethanol)
for 10 min at RT. Afterwards the staining solution was
washed out with 3 × 100 μl washing buffer (DPBS with
0.05% Tween 20) per well and the plate was dried on air.
For resolving the colorant wells were incubated with
100 μl 2% SDS (Roth) for 30 min. The adsorption was
measured at 550 nm (reference value at 650 nm) with
GloMax®-Multi detection system (Promega). Experi-
ments were performed in quadruplicates and repeated
three times.
Chemotactic cell migration assay
For chemotactic cell migration analysis a modified Boy-
den chamber was used (Costar), as described previously
[21]. The chamber consists of an upper and a lower de-
partment separated by a porous polycarbonate mem-
brane with 8 μm pore diameter (Neuro Probe). Before
analysis cells were cultivated in serum-free culture
medium for 24 h. According to the instruction of the
manufacturer, the lower chemotaxis compartment was
filled with 29 μl solution of extracellular matrix compo-
nents (according to the optimal conditions [22]: fibro-
nectin 10 μg/ml, vitronectin 5 μg/ml, laminin 50 μg/ml,
collagen I and IV 10 μg/ml (Thermo Scientific)) diluted
in serum-free medium. The lower part was covered by
the polycarbonate membrane, having been equilibrated
in DPBS for 2 min. Then the upper part was fixed. The
wells of the upper part were filled with 50 μl of tumor
cell suspension (3 × 105 cells/ml). The chamber was then
incubated for 16 h in a moistened atmosphere with 5%
CO2 at 37 °C. Afterwards not-migrated cells were re-
moved from the upper membrane side by washing it in
buffer solution according to Weise (Merck) and by
mechanical detachment using a rubber scraper. Migrated
cells were fixed in methanol for 1 min and dyed with
hemacolor (Merck). The dyed membrane was trans-
ferred onto a microscope slide and covered with
immersion oil. The migrated cells were counted on an
area of 2.5 mm2 of the porous membrane. The experi-
ment was performed in quadruplicates and repeated
three times.
Cell death detection assay
For apoptosis analysis in transfected RCC cells a cell death
detection assay (Roche) was performed. 5 × 104 cells were
seeded in a 6-well-plate. Next day medium was discarded;
cells were scraped off and transferred in 500 μl incubation
buffer. After 30 min at RT a centrifugation at 20000 g for
10 min followed. The supernatant was used for cell death
detection assay. For the assay the 96-well-plate was incu-
bated with 100 μl coating solution per well over night at
4 °C. Next day the solution was discarded, 200 μl incuba-
tion buffer was added per well and incubated for 30 min
at RT. A washing step with 300 μl washing solution per
well followed for three times. 100 μl of the prepared
supernatant was then filled in the wells. After 90 min the
solutions were discarded and wells were washed again
(3 × 300 μl/well washing solution). Incubation with 100 μl
per well coating solution for 90 min at RT followed. After
another washing step apoptosis was detected with 100 μl
substrate solution per well. The adsorption of individual
wells was measured at 405 nm with GloMax®-Multi detec-
tion system (Promega). Experiments were performed in
quadruplicates and repeated three times. Mean value and
standard error rate were calculated.
Breuksch et al. Cell Communication and Signaling  (2018) 16:35 Page 4 of 15
Cell proliferation assay
To study the effect of transfected RCC cells on prolifera-
tion, a colorimetric BrdU incorporation assay (Roche) was
performed as previously published [23]. The cells were
seeded in quadruplicates into a 96-well-plate (5 × 103
cells/well) and cultured for 48 h. BrdU solution (10 μM)
was added to the cells and incubated for 2 h. The cells
were fixed and the DNA was denatured in one step by
adding 200 μl per well fixDenat solution for 30 min. Incor-
porated BrdU was detected by an anti-BrdU-POD anti-
body (100 μl antibody solution per well) within 60 min.
Fixed cells were washed three times with 200 μl washing
solution per well. The BrdU-antibody complex was de-
tected by 100 μl substrate solution per well. After incuba-
tion of 15 min reaction was stopped by adding 25 μl
H2SO4 (1 M) per well and proliferation was quantified by
measuring the absorbance at 450 nm (reference 690 nm)
with GloMax®-Multi detection system (Promega).
Flow cytometric analysis of integrin subunits in renal
carcinoma cell lines
The stably transfected 786-O and A498 cells were ana-
lyzed for the protein levels of integrin subunits α1, α2,
α3, α5, αV, α6, β1 and β3. For this, cells were detached,
centrifuged and washed with DPBS. Tumor cells (0.5 ×
106 cells) were resuspended in 100 μl DPBS + 1% BSA
and treated with labeled anti-integrin subunit antibodies
(integrin α1/CD49a PE-conjugated, integrin α3/CD49c
Fluorescein-conjugated, integrin α6/CD49f Alexa Fluor
488-conjugated, integrin αV/CD51 PE-conjugated (all
purchased from R&D Systems) and integrin α2/CD49b
FITC-conjugated, integrin α5/CD49e PE-conjugated, in-
tegrin β1/CD29 PE-conjugated, integrin β3/CD61
FITC-conjugated (all purchased from Becton, Dickinson
& Company) for 30 min on ice in darkness. Cells were
washed by using DPBS and resuspended in 500 μl DPBS
+ 1% BSA for analysis. Fifteen-thousand counts were
used for analysis (BD Calibur, Becton, Dickinson &
Company). Protein expression analyses were performed
three times.
Human phospho-kinase array
The activity of 46 intracellular signaling kinases was
quantified by using a human phospho-kinase array
(R&D, Minneapolis, USA). The kinase array was per-
formed according to the instructions in the manual. Pro-
tein extracts from RCC cells were prepared by using
200 μl lysis buffer 6 included in the kit. The cells were
rinsed twice with ice-cold DPBS and scraped off with a
cell scraper in lysis buffer. After 30 min incubation on
ice, the extracts were centrifuged at 14000 g, 4 °C for
10 min. Protein concentrations were determined using
BCA-reagents (Pierce BCA Protein assay kit, Thermo
Scientific). The phospho-kinase array membranes were
incubated with array buffer 1 for 1 h on a rocking plat-
form. On each membrane 1 ml of the protein lysates
(300 μg) was added and incubated overnight at 4 °C on a
rocking platform. The membranes were washed three
times with washing buffer and shaken with antibody
cocktails for 2 h. After a 30-min treatment with
streptavidin-HRP solution, the membranes were exposed
to a chemiluminescent reagent. Signals were visualized
using a chemiluminescent detector (FluorChemE, Pro-
tein Simple). For quantification a computer-based pixel
counting system was used (AlphaView, Protein Simple).
Western blot analysis
For preparation of protein extracts from cell culture,
tumor cells (7.5 × 105 cells) were seeded on 100 mm2 cell
culture plates. For protein extraction, cells were washed
with DPBS and mechanically detracted in lysis buffer
(2 mM HEPES, 0.02 M NaCl, 0.05 mM MgCl2, 0.04 mM
EDTA, 0.1% Triton X-100, 5 μM DTT, 1% Phosphatase
Inhibitor Cocktail II (Sigma), 1% Protease Inhibitor
Cocktail (Sigma)) with a cell scraper [24]. The solution
was transferred into a 2 ml reaction tube and placed on
ice. After incubation for 30 min on ice the samples were
centrifuged for 10 min at 14000 g. The supernatant was
transferred to a new tube and stored at − 20 °C. For
evaluating protein concentrations of the extracts,
BCA-reagents (Pierce BCA Protein assay kit, Thermo
Scientific) were used. For protein precipitation 9-fold
volume of acetone was used.
Equal amounts of protein (50 μg per lane) were sepa-
rated by size using SDS-PAGE with 10% or 7.5% poly-
acrylamide gels. Afterwards gels were transferred on
PVDF membrane by semi-dry blotting. Membranes were
blocked according to instruction of antibody manufac-
turers for 1 h. Next, membranes were incubated with a
primary antibody in blocking solution overnight at 4 °C
on a roll mixer. The monoclonal antibodies against AKT,
phospho-AKT S473 and T308, p38, phospho p38 (T180/
Y182), PTEN (138G6), SAPK/JNK, phospho SAPK/JNK
(T183/Y185) and V5-tag (all CST) were used at a dilution
of 1:1000. β-actin antibody (Sigma) was employed at a di-
lution of 1:5000. After washing, the membranes were in-
cubated with HRP-linked secondary antibodies (DAKO)
at a dilution of 1:1000 for 1 h at RT and after washing
bound antibodies were visualized by adding enhanced
chemiluminescent solution (Perkin/Elmer) and detected
in a chemiluminescent detector (FluorChemE, Protein
Simple). For quantification bands were quantified by
densitometry evaluation using a computer-based pixel
counting system (AlphaView, Protein Simple). These
values were referred to β-actin values of the same mem-
brane as loading control. The cell culture experiments
were performed three times.
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Statistical analysis
For statistical analysis we used IBM-SPSS 22.0 and
Microsoft Excel 2013. Expression results were quantified
and presented as relative units. Significances of tissue
specimen analyses were calculated by using the Log
Rank test in relation to lymph node metastasis and over-
all survival. Regression analyses were performed by using
a Pearson correlation. All other results using RCC cell
lines were presented in % of control cells. Differences in
expression levels, activity levels, apoptosis rates, adhe-
sion and migration potential were performed using the
Student’s T-test. Statistical significance was assumed at a
p-value of < 0.05.
Results
In the primary tumor of RCC patients PTEN-Δ expression
correlates negatively with tumor progression
The expression level of PTEN-Δ and PTEN was examined
by Real-Time PCR in a cohort of 71 patients with RCC
(Table 1). For analysis patients were distinguished in two
groups, one with an expression value over median and
one with an expression value less or equal to the median
expression. Patients with a lower PTEN-Δ expression
(PTEN-Δ ≤median expression value) showed a signifi-
cantly higher rate of lymph node metastasis than patients
with a higher PTEN-Δ expression (PTEN-Δ >median ex-
pression value) (Fig. 2a, p = 0.024). For PTEN expression
this relationship was not significant (Fig. 2a, p = 0.081).
Concerning the PTEN expression value we could confirm
its role as a tumor suppressor in our cohort, since patients
with a high PTEN expression (PTEN >median value) had
a better overall survival (Fig. 2b, p = 0.03). Furthermore,
patients with a higher PTEN-Δ expression value tend to
have a higher overall survival. In the first 5 years of
follow-up the Kaplan-Meier curve of survival drifts be-
tween low and high PTEN-Δ expressing patients, but in
the further course no significant difference was observed
(Fig. 2b, p = 0.365). Patients who showed a high expres-
sion value in both PTEN-Δ and PTEN (> median) had a
significantly longer survival compared to patients with low
PTEN-Δ and simultaneously low PTEN expression value
(< median) (Fig. 2c, p = 0.036). However, a combination of
low PTEN/ PTEN-Δ expression or a combination of high
PTEN/ PTEN-Δ expression was no independent predictor
for survival or metastasis, as found by multivariate ana-
lyses (Cox regression), using histology, grading, staging
and patient’s age for covariates (data not shown). The ex-
pression value of PTEN correlated with the expression
level of its splice variant PTEN-Δ. While a low (≤ median)
PTEN-Δ expression correlated with a low PTEN expres-
sion (35.21% of the patients), a high (> median) PTEN-Δ
expression correlated with a high PTEN expression
(35.21% of the patients). This correlation was significant
(Table 2, p = 0.001).
In RCC cells PTEN-Δ mRNA is translated into a PTEN-Δ
protein
For analysis of the cellular function of PTEN-Δ we
aimed to create PTEN-Δ overexpressing RCC cells,
which endogenously express low level of PTEN-Δ. We
screened the native expression of PTEN-Δ and PTEN by
qRT-PCR in the RCC cell lines A498, 786-O, Caki-1,
Caki-2, CCF-RCI and CCF-RCII. While Caki-1 and
Caki-2 cells showed a high PTEN-Δ expression (3.56 and
3.19, relative units), in A498 and 786-O cells PTEN-Δ
was relatively low expressed (1.02 and 0.66, relative
units) (Fig. 3a). For determining the translation capabil-
ity of PTEN-Δ we generated PTEN-Δ or PTEN in a
cell-free in vitro translation (IVT), as a positive control.
To study the influence of PTEN-Δ on tumor progres-
sion, we stably overexpressed PTEN-Δ and, for a com-
parison, PTEN in the PTEN-Δ low expressing RCC cell
lines A498 and 786-O. A498 cells endogenously express
a functional PTEN, the 786-O cells contain a mutation
in the PTEN gene. As expected, Western blot analysis of
these two cell lines verified that only A498 cells express
endogenous PTEN on protein level (Additional file 1:
Figure S1). After stable transfection, PTEN-Δ and PTEN
were detectable on protein level in these cells, visualized
by the use of an anti-V5-tag antibody (Fig. 3b), since no
useable antibody for detection of PTEN-Δ could be
found. The V5 tag-sequence was fused in frame to the
3′-end of the ORF of the PTEN-Δ and PTEN isoform, so
that after translation it is located at the C-terminus of
the protein. Overexpression of PTEN-Δ as well as PTEN
was verified by quantitative RT-PCR with specific
primers in both cell lines (Fig. 3c).
PTEN-Δ reduces cell migration towards and adhesion to
ECM components
We analyzed the effect of PTEN-Δ and PTEN on the
chemotactical cell migration and cell adhesion in stably
transfected 786-O and A498 cells. In 786-O cells overex-
pression of PTEN-Δ as well as PTEN resulted in a sig-
nificant reduced migration using ECM components
fibronectin, vitronectin, laminin, collagen I and IV as
chemotaxins, compared to pcDNA3 vector transfected
cells as control. The migration potential was decreased
between 37 and 68% (Fig. 4a). In stably transfected A498
cells overexpression of PTEN-Δ induced a significant re-
duction in chemotactical cell migration between 34 and
67% of control, while PTEN overexpression had no effect
(Fig. 4a). In addition to cell migration we analyzed the
influence of PTEN-Δ on cell adhesion to the indicated
ECM components. Both cell lines showed a decrease in
cell adhesion in PTEN-Δ as well as in PTEN overex-
pressing cells. In 786-O cells the adhesion was reduced
between 25 and 10% for PTEN-Δ and between 34 and
18% for PTEN (Fig. 4b). In A498 cells overexpression
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Fig. 2 Influence of PTEN-Δ expression on tumor progression of RCC patients. PTEN-Δ and PTEN expression was quantified by Real-Time PCR in
tumor tissue specimens from patients with primary RCC, shock frozen after nephrectomy. Patients were grouped in two categories: patients with
a high PTEN-Δ or PTEN expression value (PTEN-Δ / PTEN > median) and in a group with low PTEN-Δ or PTEN expression value (PTEN-Δ / PTEN ≤
median). a The Kaplan-Meier curves show the lymph node metastasis rate of patients with high PTEN-Δ or PTEN expression value compared to
patients with a low PTEN-Δ or PTEN expression in RCC tissue. Significance was calculated by a Log Rank test, p < 0.05. b The Kaplan-Meier curves
show the overall survival of patients with high/low PTEN-Δ or PTEN expression value in RCC tissue. Significance was calculated by a Log Rank test,
p < 0.05. c Comparison of time to death of patients with high PTEN-Δ and simultaneously high PTEN expression value (> median) and patients
with low PTEN-Δ and simultaneously low PTEN expression (< median). Significance was calculated by a Mann-Whitney-U test, p < 0.05
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of PTEN-Δ showed a decrease between 61 and 76%
comparing to pcDNA3 transfected cells. Overexpres-
sion of PTEN showed a similar effect with a reduced
adhesion of 59 and 39% (Fig. 4b). In contrast, the
proliferation was not influenced by either PTEN-Δ or
PTEN overexpression (Additional file 2: Figure S2).
The apoptosis rate is slightly triggered by PTEN-Δ
The apoptosis rate was determined by a cell death detec-
tion assay. In 786-O cells, PTEN-Δ triggered the apop-
tosis rate to 140% (not significant) comparing to
pcDNA3 transfected control cells (Fig. 4c). In A498 cells
overexpression of both PTEN-Δ and PTEN induced an
enhanced apoptosis rate of 133% (p = 0.006) and 152%
(p = 0.008), respectively (Fig. 4c).
Knockdown of PTEN-Δ increases migration potential in
Caki-1 cells
To verify the influence of PTEN-Δ on cellular pro-
cesses, we exemplarily analyzed the effect of PTEN-Δ
reduction on chemotactical migration in native
PTEN-Δ expressing cells. Since Caki-1 RCC cells
showed the highest expression of PTEN-Δ (Fig. 3a),
we used these cells to study the effect of siRNA
knockdown of PTEN-Δ. Knockdown efficiency of 68%
(p < 0.001) was achieved, verified by qRT-PCR
(Fig. 5a). We analyzed the influence of PTEN-Δ
knockdown on chemotactical migration using fibro-
nectin as chemotaxin. The PTEN-Δ knockdown in-
creased the migration potential to 145% (p = 0.04),
compared to scrambled locus (negative control) trans-
fected cells (Fig. 5b).
Table 2 Cross table of PTEN-Δ and PTEN expression in tissue of 71 RCC patients
PTEN ≤ median expression value PTEN > median expression value
PTEN-Δ ≤median expression value 25 (35.21%) 11 (15.49%)
PTEN-Δ >median expression value 10 (14.08%) 25 (35.21%)
The PTEN expression value correlates with the PTEN-Δ expression value. Significance was calculated by a Chi-Square test p < 0.05
a
c
b
Fig. 3 Expression of PTEN-Δ in RCC cell lines and translation of PTEN-Δ in RCC cells. a Relative expression values of PTEN-Δ in RCC cell lines were
quantified by Real-Time PCR. Expression was normalized to expression of the house-keeping genes TBP, ATP5J and PPIA. b 786-O and A498 cells
were transfected with the expression construct for the PTEN-Δ and PTEN isoform, C-terminally tagged with a V5-tag to enable detection of the
PTEN-isoforms. Western blots of 786-O cell protein extracts were thus performed with an anti-V5-tag antibody. As positive control for the
transfected constructs, cell free in vitro translated (IVT) protein of the respective construct was loaded. c Expression of PTEN-Δ and PTEN in
transfected 786-O and A498 RCC cells were quantified by Real-Time PCR. Results show relative expression value of PTEN-Δ or PTEN compared to
control cells (pcDNA3 transfected cells). Significance was calculated by Student‘s T-test, *p < 0.05
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Integrin expression is influenced by PTEN-Δ
To examine whether the reduced migration and adhe-
sion potentials are induced via an altered integrin ex-
pression, the integrin subunit expression of α1, α2, α3,
α5, αV, α6, β1 and β3 were analyzed in the PTEN-Δ or
PTEN overexpressing RCC cells. Both overexpressed
isoforms reduced expression of integrin subunit α1 in
786-O cells (PTEN-Δ: 67.5%, not significant; PTEN:
67.2%, p = 0.007) as well as in A498 cells (PTEN-Δ:
56.2%, not significant; PTEN: 80.8%, p = 0.022) (Fig. 6a).
Expression of integrin subunit α5 in 786-O cells was re-
duced to 74.2% (p = 0.029) in PTEN-Δ overexpressing
a
b
c
Fig. 4 Influence of PTEN-Δ and PTEN on the functional behavior of renal tumor cells. a Migration of PTEN-Δ or PTEN transfected 786-O and A498
cells was determined in a Boyden chamber using ECM compounds as chemotaxins (FN: Fibronectin, VN: Vitronectin, LM: Laminin, CI: Collagen I
and CIV: Collagen IV). Differences are shown in percentage of control cells (pcDNA3 transfected cells). b Cell adhesion of PTEN-Δ or PTEN
transfected 786-O and A498 cells on immobilized ECM compounds were determined. BSA was used as control (Data not shown). Differences are
shown in percentage of control cells (pcDNA3 transfected cells). c Apoptosis values of PTEN-Δ or PTEN transfected 786-O and A498 cells were
quantified by determination of cytoplasmic histone-associated DNA fragments (Cell death detection assay, Roche). Differences are shown in
percentage of control cells (pcDNA3 transfected cells). Significance was calculated by Student‘s T-test, *p < 0.05
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cells and up to 70% (not significant) in PTEN overex-
pressing cells. In contrast in A498 cells, the integrin
α5 expression was only in PTEN-Δ overexpressing
cells reduced to 57.4% (not significant) but not in
PTEN overexpressing cells (Fig. 6b). Integrin αV
showed no effect in 786-O cells, but a decreased ex-
pression in PTEN-Δ and PTEN overexpressing A498
cells (not significant) (Fig. 6c). Integrin β1 expression
was only decreased in PTEN-Δ overexpressing A498
cells (PTEN-Δ: 58.3%, p = 0.003) (Fig. 6d). All other
integrin subunits tested were unchanged by PTEN-Δ
or PTEN overexpression. These results demonstrate
that PTEN-Δ, like PTEN, seems to regulate specific
integrin subunit expression and inhibit migration and
adhesion processes. Furthermore, we determined the
integrin expression in Caki-1 cells after PTEN-Δ
knockdown. Integrin α5 expression was slightly in-
creased (+ 17%, p < 0.001) after knockdown of
PTEN-Δ comparing to negative control (scrambled
locus) (Fig. 5c).
PTEN-Δ inhibits AKT and MAPK signaling cascade
Since PTEN-Δ inhibits cellular processes which par-
ticipate in tumor progression, the involved signaling
cascades were analyzed. We performed a human
phospho-kinase array including 46 intracellular ki-
nases (Additional file 3: Figure S3). The activities of
the kinases were measured by detecting the expres-
sion of the phosphorylated molecules. Afterwards dif-
ferences in activity levels exceeding 20% were verified
by Western blot analysis. The activity of examined
signaling molecules showed differences in the two
RCC cell lines. In 786-O cells the strongest PTEN-Δ
induced reduction was observed for phosphorylated
AKT (T308) to 38.7% (p < 0.001), whereas PTEN re-
duced the T308 phosphorylation of AKT to 53.6%
(p = 0.016) (Fig. 6e). Furthermore, in PTEN-Δ and
PTEN overexpressing 786-O cells a moderate de-
crease of phosphorylated AKT (S473) and p38 kinase
(T180/Y182) compared to pcDNA3 transfected cells
was detected (Fig. 6f, g). In contrast, PTEN-Δ and
a b c
d e
Fig. 5 Verification of the role of PTEN-Δ. a The PTEN-Δ expression value of Caki-1 cells (native highly PTEN-Δ expressing) after PTEN-Δ siRNA
knockdown (KD) was determined by Real-Time PCR. Expression was normalized to expression of the housekeeping genes TBP, ATP5J and PPIA and
is shown as percentage of the expression of the nonsense siRNA transfection control (scrambled locus). Expression of PTEN-Δ was reduced to
32%. b Migration of Caki-1 cells after PTEN-Δ siRNA knockdown was determined in a Boyden chamber using fibronectin (10 μM) as chemotaxin.
The migration value is shown as percentage of the migration of the scrambled locus siRNA transfection control. c Integrin α5 expression value of
Caki-1 cells after PTEN-Δ knockdown was determined by flow cytometry. The expression value is shown as percentage of the transfection control
(scrambled locus siRNA transfected negative control). Phosphorylation of AKT (S473) (d) and p38 (T180/Y182) (e) in Caki-1 cells after PTEN-Δ
knockdown was determined by Western blot and quantified by densitometric evaluation of the bands. Results are shown as percentage of siRNA
control transfected cells (scrambled locus). Significance was calculated by Student’s T-test, *p < 0.05
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PTEN overexpressing A498 cells showed a strong de-
crease of c-Jun N-terminal kinase (JNK) (T183/Y185)
activity value (PTEN-Δ: 50.2%, p = 0.011; PTEN:
50.3%, p = 0.022) (Fig. 6h). In A498 cells the activity
of the kinase p38 (T180/Y182) was also slightly re-
duced compared to control vector transfected cells
(Fig. 6g). The kinase AKT showed a reduced phos-
phorylation on position T308 (Fig. 6e) only in
PTEN-Δ overexpressing A498 cells. In addition, we
determined the kinase activity in Caki-1 cells after
PTEN-Δ knockdown. The kinase AKT showed an in-
creased phosphorylation on S473 (+ 57%, p = 0.03)
after knockdown of PTEN-Δ (Fig. 5d). The p38 kinase
activity was also increased (to 176%) after PTEN-Δ
knockdown compared to the transfection control
(scrambled locus) (Fig. 5e). These results suggest a
contribution of PTEN-Δ in regulation of both, AKT
and MAPK, signaling cascades.
a b
c d
e f
g h
Fig. 6 Influence of PTEN-Δ and PTEN on cell signaling. Expression of integrin α1 (a), integrin α5 (b) integrin αV (c) and integrin β1 (d) in RCC cells
were determined in PTEN-Δ and PTEN transfected cells by flow cytometry. Representative histograms are shown for each staining. Expression
value is shown as percentage of expression of the pcDNA3 transfected control cells. Significance was calculated by Student‘s T-test, *p < 0.05.
Phosphorylation of AKT (T308) (e), AKT (S473) (f), p38 (T180/Y182) (g) and JNK (T183/Y185) (h) in transfected 786-O and A498 cells was
determined by Western blot. Representative Western blots are shown for each kinase. Activity value was determined by densitometric evaluation
and is shown as percentage of activity of the pcDNA3 transfected cells. Significance was calculated by Student‘s T-test, *p < 0.05
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Discussion
The tumor suppressor PTEN/MMAC1/TEP1 is known
to be a regulator of cellular processes like cell prolifera-
tion, migration, motility and apoptosis [14, 25, 26], being
frequently mutated in tumor cells. The cancer genome
atlas identified more than 1120 mutations in 27 different
tumor entities [27]. In RCC, several studies could show
that PTEN shows a lower expression in tumor tissues
compared to normal renal tissue and that patient’s with
a higher expression in tumor tissue had a better out-
come in context of survival and metastasis [5, 28, 29].
In this study we analyzed the impact of PTEN’s splice
variant PTEN-Δ in tissues of patients with RCC. PTEN-Δ
results from inclusion of intron 8 (Fig. 1). Consequently,
the protein lacks the 61 amino acids of exon 9 which
should be replaced by a valine and serine from intron 8
[16]. We demonstrate a putative contribution of the
splice variant in tumor progression. Patients with high
PTEN-Δ expression had a significantly lower risk of de-
veloping lymph node metastases. During the first 5 years
of follow-up also patient’s cell death seems to occur fas-
ter when expressing PTEN-Δ low in tumor tissue. These
results suggest that PTEN-Δ is likely to have a tumor
suppressive role in RCC. Expression analyses of PTEN in
our cohort confirmed its tumor suppressive role. Pa-
tients with a higher PTEN expression value had a signifi-
cantly longer overall survival and tended to have a
longer lymph node metastasis free survival. Patients with
both, a high PTEN-Δ and a high PTEN expression value,
had a significant longer time to death, indicating that
both variants are important factors in regulating tumor
processes. Furthermore, we analyzed the effect of
PTEN-Δ on specific steps of tumor progression and me-
tastasis in vitro. By using a V5-tag we could show for the
first time that PTEN-Δ is translated and expressed on
protein level in tumor cells. The splice variant lacks
parts of the C2 domain and the C-terminal domains: the
C-tail and the PDZ-binding domain (Fig. 1). These do-
mains take part in PTEN’s stability and activity, since
they contain many modification sites. By its
PDZ-binding domain PTEN can interact with proteins
containing also a PDZ domain, or with proteins that
have a PtdIns(4,5)P2 motif. The membrane proteins
MAGI, PAR-3, MAST, SAST and NEP, which contain
such binding domains, are well-known examples of this
fact. They can interact with PTEN and recruit the phos-
phatase to the membrane [30–32]. Localization of the
protein to the membrane is also triggered via SUMOyla-
tion, whereas inhibition of this recruitment is regulated
by phosphorylation of the C-tail, indicating that subcel-
lular localization of PTEN is governed by a sensitive bal-
ance of modifications [33, 34]. Georgescu and colleagues
could show that mutations in the C-terminal region lead
to an instable, highly degradable protein [35]. In contrast,
a deletion-mutant of PTEN shortened by 67 amino acids
showed unchanged protein stability and functional prop-
erties [10]. These observations suggest that PTEN-Δ is
stable and exerts phosphatase features in vitro.
Our functional analysis of important steps of tumor
progression and metastasis showed that PTEN-Δ, like
PTEN, acts in a tumor suppressive manner. PTEN-Δ
overexpressing RCC cells had a lower migration poten-
tial towards ECM components, a reduced adhesion to
these and showed an enhanced apoptosis rate. Analysis
of the molecular setting showed a reduced expression of
the integrin subunits α1, α5, αV and β1 as well as a de-
crease in JNK, p38 and AKT activity. Similar to the im-
pact of PTEN-Δ on tumor progression in vivo,
overexpression of PTEN in RCC cell lines 786-O and
A498 also induced a reduced cell migration, reduced ad-
hesion and enhanced apoptosis. These effects of PTEN
were more intense in the cell line 786-O, which carries a
mutation in PTEN gene (c.445C > T), than in A498 cells
which already express PTEN endogenously. Probably
A498 cells acquired a PTEN tolerance regarding tumor-
ous effects and therefore are less affected by a PTEN
overexpression. In glioma cells, Raftopoulou and col-
leagues could show that PTEN mediates cell migration
processes via its C2 domain in a PI3K independent man-
ner [25]. Further investigations demonstrated that PTEN
intervenes in an integrin cascade, which triggered cell
migration via tyrosine kinases of the SRC family [36].
Comparably we could show in former studies that PTEN
regulates migration processes in 786-O cells via its pro-
tein phosphatase activity in a SHC dependent signaling
cascade [10]. Here, we could demonstrate that PTEN-Δ
as well as PTEN overexpression leads to a decrease in
integrin subunit α1, α5 and αV expression, and that also
the MAPK’s JNK and p38 showed a reduced activity
value. Furthermore, we could show that a knockdown of
PTEN-Δ lead to an increase in integrin α5 expression
and a higher activity of the kinases AKT and p38. While
β1 integrin together with α1 forms a heterodimer recep-
tor for laminin and collagens, an α5/β1 complex forms a
receptor for fibronectin and an αV/β1 dimer for vitro-
nectin [37]. Corresponding to the reduced integrin ex-
pression the migration in direction and adhesion to
these ECM components was reduced. This data suggests
that PTEN-Δ inhibits cell migration and adhesion via in-
tegrin and MAPK signaling cascade similar to PTEN. A
contribution of JNK in the MAPK cascade to PTEN
regulation has already been shown by Vivanco and col-
leagues [38]. The results indicate that PTEN-Δ and
PTEN possibly regulate migration and adhesion pro-
cesses via a changed integrin subunit expression and
downstream via the MAPK signaling cascade. On the
other hand it is also possible that the reduced activity of
MAPK signaling cascade induces the decreased integrin
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expression and subsequently leads to the reduced cellu-
lar processes. The PI3K is the main antagonist of PTEN,
which dephosphorylates PtdIns(3,4,5)P3 signaling mes-
sengers and thereby inhibits downstream AKT activation
[2]. We can observe a decrease in AKT activity in
PTEN-Δ and PTEN overexpressing 786-O cells. Like in
Schneider and colleagues in RCC cells [10], we can con-
firm a contribution of PTEN in this regulation. We show
that also PTEN-Δ is capable to reduce AKT phosphoryl-
ation and therefore can inhibit this signaling cascade.
Cellular signaling processes downstream of AKT, like
cell proliferation, migration and apoptosis, get conse-
quently modified. Cell proliferation was neither influ-
enced in PTEN-Δ nor PTEN overexpressing RCC cells
(Additional file 2: Figure S2) although it has been de-
scribed that PTEN is able to regulate these processes
[39]. This indicates that in the used RCC cells prolifera-
tion is regulated via different signaling cascades.
A498 cells endogenously have a functional PTEN, while
in 786-O cells the PTEN gene bears a mutation. In both
cell lines a similar impact of PTEN-Δ overexpression on
the analyzed cellular processes could be observed. Effects
in A498 cells are more intense compared to 786-O cells,
arguing for some kind of synergistic effect of both
isoforms probably through interactions or dimerization of
the isoforms, a function which was recently shown by
Papa and colleagues [40]. Our results indicate that
PTEN-Δ acts as a new tumor suppressor for RCC. An
artificial effect of the synthetic PTEN-Δ overexpression is
unlikely, since knockdown of PTEN-Δ in Caki-1 cells
confirmed our finding by leading to a drop of migration
potential when using fibronectin as chemotaxin. The
splice variant acts probably in a similar fashion as the full
length protein PTEN via the integrin and MAPK cascade
and by inhibiting the AKT pathway. In this way it may
diminish and finetune cellular processes like migration,
adhesion and prevention of apoptosis (Fig. 7).
Conclusions
The diversity of the tumor suppressor protein PTEN is
substantiated by its diverse splice variants. These splice
variants might also take part in tumor progression pro-
cesses. Our data demonstrates that PTEN-Δ acts similar
to PTEN in a tumor suppressive manner. Knowledge
about the detailed individual function of PTEN-Δ and
other splice variants of PTEN in the context of tumor
progression might uncover new therapeutic options in
RCC and other tumor entities.
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